Recent Biotech Buyouts at a Large Premium [Added MEDI and PHRM deals. Table excludes hostile deals not yet consummated such as Roche-DNA and BMY-IMCL.]<pre> Acquired Premium Deal iHub Company Buyer to Market Value Date Reference KOSN BMY 233% $190M 5/08 <a href='read_msg.asp?message_id=29647147'>#msg-29647147</a> COLY PFE 167% $165M 11/07 <a href='read_msg.asp?message_id=24600805'>#msg-24600805</a> IOMI Intercell 147% $190M 5/08 <a href='read_msg.asp?message_id=29232165'>#msg-29232165</a> BTRX Stiefel 136% $150M 6/08 <a href='read_msg.asp?message_id=30201906'>#msg-30201906</a> SGXP LLY 119% $64M 7/08 <a href='read_msg.asp?message_id=30547648'>#msg-30547648</a> ENCY PFE 118% $350M 2/08 <a href='read_msg.asp?message_id=26978155'>#msg-26978155</a> TRCA Ipsen 104% $660M 6/08 <a href='read_msg.asp?message_id=29795183'>#msg-29795183</a> Speedel NVS 94% $880M 7/08 <a href='read_msg.asp?message_id=30588524'>#msg-30588524</a> SIRT GSK 85% $620M 4/08 <a href='read_msg.asp?message_id=28705020'>#msg-28705020</a> Ventana Roche 72% $3.4B 1/08 <a href='read_msg.asp?message_id=30912677'>#msg-30912677</a> Jerini Shire *71% $520M 7/08 <a href='read_msg.asp?message_id=30452872'>#msg-30452872</a> Acambis SNY 64% $550M 7/08 <a href='read_msg.asp?message_id=30990498'>#msg-30990498</a> MEDI AZN ‡‡53% $15.2B 4/07 <a href='read_msg.asp?message_id=19020387'>#msg-19020387</a> MLNM Takeda 53% $8.8B 4/08 <a href='read_msg.asp?message_id=28365383'>#msg-28365383</a> LEVP VPHM ††49% $440M 7/08 <a href='read_msg.asp?message_id=30704409'>#msg-30704409</a> PHRM CELG 46% $2.9B 11/07 <a href='read_msg.asp?message_id=24645394'>#msg-24645394</a> BRL TEVA **42% $9.0B 7/08 <a href='read_msg.asp?message_id=30792830'>#msg-30792830</a> MOGN Eisai 39% $3.9B 12/07 <a href='read_msg.asp?message_id=25163775'>#msg-25163775</a> CGPI Galderma 30% $420M 2/08 <a href='read_msg.asp?message_id=28286522'>#msg-28286522</a> APPX Fresenius †29% $940M 7/08 <a href='read_msg.asp?message_id=30498388'>#msg-30498388</a> ARI.to Roche ‡15% $190M 7/08 <a href='read_msg.asp?message_id=30904056'>#msg-30904056</a> *199% premium to volume-weighted price during preceding 3 months. **Premium based on 7/16/08 close; $9B price includes assumption of debt. †Premium reaches 63% if earn-out met. ††Premium reaches 103% if earn-out met; base price subject to collar. ‡Number is misleading inasmuch as Arius announced in May 2008 that it was pursued by an unnamed suitor. ‡‡Premium relative to 4/11/07 close; MEDI announced intention to be sold on 4/12/07.</pre> <!--Beg_Sig--> “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”